200 related articles for article (PubMed ID: 34619840)
1. [Efficacy and safety of anti-PD-1 monoclonal antibody in advanced hepatocellular carcinoma after TACE combined with TKI therapy].
Xu ZN; Huang JJ; Zhou J; Huang WS; Guo YJ; Cai MY; Zhou JW; Lin LT; Liang LC; Zhu KS
Zhonghua Nei Ke Za Zhi; 2021 Jul; 60(7):630-636. PubMed ID: 34619840
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis.
Xian F; Song XW; Bie J; Zhao CX; Zhang GJ; Xu GH
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):687-701. PubMed ID: 38305611
[TBL] [Abstract][Full Text] [Related]
4. Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib.
Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
J Gastrointest Oncol; 2022 Aug; 13(4):1907-1914. PubMed ID: 36092351
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.
Xie D; Sun Q; Wang X; Zhou J; Fan J; Ren Z; Gao Q
Ann Transl Med; 2021 Apr; 9(8):652. PubMed ID: 33987350
[TBL] [Abstract][Full Text] [Related]
6. Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.
Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
J Gastrointest Oncol; 2022 Jun; 13(3):1248-1254. PubMed ID: 35837179
[TBL] [Abstract][Full Text] [Related]
7. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apatinib and transcatheter arterial chemoembolization as second-line therapy for advanced hepatocellular carcinoma: A retrospective cohort study.
Li T; Zhao J; Zhang S; Wang H; Sun L; Hu J
J Cancer Res Ther; 2023 Feb; 19(1):57-63. PubMed ID: 37006043
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
13. [Clinical value of iodine [131I] metuximab infusion combined with TACE for treatment of patients with post-intervention relapse of mid or advanced stage hepatocellular carcinoma].
Li Z; Zhou JX; Ren JZ; Zhang WJ; Han XW
Zhonghua Gan Zang Bing Za Zhi; 2013 Oct; 21(10):728-33. PubMed ID: 24331628
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study.
Huang Z; Wu Z; Zhang L; Yan L; Jiang H; Ai J
Front Oncol; 2024; 14():1298122. PubMed ID: 38318115
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.
Qin J; Huang Y; Zhou H; Yi S
Front Oncol; 2022; 12():807102. PubMed ID: 35463356
[TBL] [Abstract][Full Text] [Related]
16. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of transcatheter arterial chemoembolization combined with 125I seed implantation and three-dimensional conformal radiotherapy in advanced primary hepatocellular carcinoma.
Zhang H; Yang A; Zhang J
J BUON; 2020; 25(2):952-958. PubMed ID: 32521891
[TBL] [Abstract][Full Text] [Related]
18. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.
Li J; Kong M; Yu G; Wang S; Shi Z; Han H; Lin Y; Shi J; Song J
Front Immunol; 2023; 14():1188308. PubMed ID: 37545497
[TBL] [Abstract][Full Text] [Related]
20. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
